Clinical Course and Prognosis of Smoldering (Asymptomatic) Multiple Myeloma
Open accessThe DOI matches its Crossref record; 24 of the 25 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Smoldering (asymptomatic) multiple myeloma is an asymptomatic plasma-cell proliferative disorder associated with a high risk of progression to symptomatic multiple myeloma or amyloidosis. Prognostic factors for the progression and outcome of this disease are unclear. METHODS: We searched a computerized database and reviewed the medical records of all patients at Mayo Clinic who fulfilled the criteria of the International Myeloma Working Group for the diagnosis of smoldering multiple myeloma between 1970 and 1995. Bone marrow aspirate and biopsy specimens were studied, and patients were followed throughout the course of disease. RESULTS: During the 26-year period, 276 patients fulfilled the criteria for smoldering multiple myeloma. During 2131 cumulative person-years of follow-up, symptomatic multiple myeloma or amyloidosis developed in 163 persons (59%). The overall risk of progression was 10% per year for the first 5 years, approximately 3% per year for the next 5 years, and 1% per year for the last 10 years; the cumulative probability of progression was 73% at 15 years. At diagnosis, significant risk factors for progression included the serum level and type of monoclonal protein, the presence of urinary light chain, the extent and pattern of bone marrow involvement, and the reduction in uninvolved immunoglobulins. The proportion of plasma cells in the bone marrow and the serum monoclonal protein level were combined to create a risk-stratification model with three distinct prognostic groups. CONCLUSIONS: The risk of progression from smoldering multiple myeloma to symptomatic disease is related to the proportion of bone marrow plasma cells and the serum monoclonal protein level at diagnosis.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Patients with SMM have a risk of progression of approximately 10% per year for the first 5 years, 3% per year for the next 5 years, and 1% per year thereafter.19”
From Multiple myeloma: 2024 update on diagnosis, risk-stratification, and management (2024) · cites this paper as [19]
Citations
Cites
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1992) · Springer Series in Statistics · doi:10.1007/978-1-4612-4380-9_25 · Cited by 45,181
Regression Models and Life-Tables
Cox, D. R. (1972) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1972.tb00899.x · Cited by 39,793
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1958) · Journal of the American Statistical Association · doi:10.1080/01621459.1958.10501452 · Cited by 39,158
Regression Models and Life-Tables
Cox, D. R. (1992) · Springer Series in Statistics · doi:10.1007/978-1-4612-4380-9_37 · Cited by 26,297
Asymptotically Efficient Rank Invariant Test Procedures
Peto, R., & Peto, J. (1972) · Journal of the Royal Statistical Society. Series A (General) · doi:10.2307/2344317 · Cited by 3,393
Gooley, T. A., Leisenring, W., Crowley, J., & Storer, B. E. (1999) · Statistics in Medicine · doi:10.1002/(sici)1097-0258(19990330)18:6<695::aid-sim60>3.0.co;2-o · Cited by 2,688
Review of 1027 Patients With Newly Diagnosed Multiple Myeloma
Kyle, R. A., Gertz, M. A., Witzig, T. E., Lust, J. A., Lacy, M. Q., Dispenzieri, A., Fonseca, R., Rajkumar, S. V., Offord, J. R., Larson, D. R., et al. (2003) · Mayo Clinic Proceedings · doi:10.4065/78.1.21 · Cited by 2,447
Self-citationThe International Myeloma Working Group (2003) · British Journal of Haematology · doi:10.1046/j.1365-2141.2003.04355.x · Cited by 2,321
A Long-Term Study of Prognosis in Monoclonal Gammopathy of Undetermined Significance
Kyle, R. A., Therneau, T. M., Rajkumar, S. V., Offord, J. R., Larson, D. R., Plevak, M. F., & Melton, L. J. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa01133202 · Cited by 1,475
Self-citationManual of Clinical Laboratory Immunology
Rose, N. R., Hamilton, R. G., & Detrick, B. (1992) · Cited by 1,250
Cited by
Items 601–700 of 932
Kastritis, E., Malandrakis, P., Kostopoulos, I. V., Ntanasis‐Stathopoulos, I., Solia, E., Theodorakakou, F., Spiliopoulou, V., Fotiou, D., Migkou, M., Kanellias, N., et al. (2025) · Blood Cancer Journal · doi:10.1038/s41408-025-01369-8 · Cited by 7
Targeting of SKP2 to combat drug resistance in multiple myeloma
Faruq, O., Ngo, J., Iyer, D., William, J. N. G., Shrestha, M., & Chang, H. (2025) · Scientific Reports · doi:10.1038/s41598-025-21719-7 · Cited by 3
“Our analysis revealed that the three drug-resistant cell lines (MM.1R, 8226R5 and OPM-2 vel/R), along with the single drug-sensitive cell line previously identified with high SKP2 expression (8226), exhibited elevated IC50 values for SkpinC1 across all time points.”
Body Composition Metrics Associated with Time to Progression in Smoldering Multiple Myeloma
Bauer, F., Huber, F. A., Galdamez, M. E., Zorgno, I., Habibollahi, S., Kandoussi, A. E., Fintelmann, F. J., Tonnesen, P. E., Dietrich, A.-S. W., Wang, Z., et al. (2025) · Diagnostics · doi:10.3390/diagnostics15212760 · Cited by 3
“In SMM, median TTP is 5 years with 73% of SMM patients progressing within 15 years of diagnosis [2].”
Early intervention for high-risk smoldering multiple myeloma (SMM)
Chen, P., Jhou, H., Ho, C., Huang, H.-L., & Lee, C.-H. (2026) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd015494.pub2 · Cited by 3
Multiple Myeloma: 2026 Update on Diagnosis, Risk‐Stratification and Management
Rajkumar, S. V. (2026) · American Journal of Hematology · doi:10.1002/ajh.70475 · Cited by 5
Self-citationSlovenske smernice za obravnavo diseminiranega plazmocitoma 2015
Zver, S., & Mlakar, U. (2015) · Slovenian Medical Journal · doi:10.6016/zdravvestn.1343 · Cited by 5
Mouhieddine, T. H., Ghobrial, I. M., & Nadeem, O. (2025) · Best Practice & Research Clinical Haematology · doi:10.1016/j.beha.2025.101641 · Cited by 4
Cantley, M. D., Trainor, L. J., Cheney, E. A.-J., Watt, S. M., & Vandyke, K. (2025) · Pathology · doi:10.1016/j.pathol.2025.11.002 · Cited by 3
How long can we let the myeloma smolder?
Usmani, S. Z. (2014) · Expert Review of Hematology · doi:10.1586/17474086.2014.874944 · Cited by 3
“The Mayo Clinic investigators, led by Kyle, have identified that 1% of the MGUS patients and 10% of the asymptomatic or smoldering MM patients would progress to symptomatic MM every year [3].”
BackgroundWyzwania wczesnej diagnostyki szpiczaka plazmocytowego – algorytm diagnostyczny
Giannopoulos, K., Dwilewicz‐Trojaczek, J., Stompór, T. P., Ligocki, P., Stopiński, M., Sutkowski, M., Grząśko, N., Morawska, M., Kordecka, A., Kordecki, M., et al. (2019) · Acta Haematologica Polonica · doi:10.2478/ahp-2019-0020 · Cited by 3
The roles of TRAF3 mutation in the oncogenic progression and drug response of multiple myeloma
Neja, S. A. (2020) · Genome Instability & Disease · doi:10.1007/s42764-020-00022-x · Cited by 3
Hradská, K., Jelínek, T., Ďuraš, J., Mihályová, J., Popková, T., Cvek, J., Bukovanský, K., Havel, M., Spáčílová, V., & Hájek, R. (2020) · Vnitřní lékařství · doi:10.36290/vnl.2020.088 · Cited by 3
“Mezistupeň mezi MGUS a mnohočetným myelomem je známý jako doutnající (smoldering) myelom, u kterého je pravděpodobnost progrese do symptomatického onemocnění asi 10 % ročně prvních 5 let, poté se snižuje (1, 8).”
Peller, P. J. (2015) · PET Clinics · doi:10.1016/j.cpet.2014.12.008 · Cited by 3
Dragos, L. M., Ivanov, I. C., Mențel, M., Văcărean-Trandafir, I.-C., Sireteanu, A., Titianu, A. A., DASCALESCU, A. S., Stache, A. B., Jitaru, D., & Gorgan, L. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23147530 · Cited by 3
“myeloma is the second stage in the development of the disease, where the infiltration of BM with clonal PCs increases compared with MGUS, but terminal organ damage symptoms related to myeloma are not yet present [9].”
BackgroundSon, A. Y., & Chung, H. W. (2022) · Journal of the Korean Society of Radiology · doi:10.3348/jksr.2021.0179 · Cited by 3
A Stepwise Screening Protocol for Multiple Myeloma
Morawska, M., Dwilewicz‐Trojaczek, J., Stompór, T. P., Ligocki, P., Stopiński, M., Sutkowski, M., Grząśko, N., Kordecka, A., Kordecki, M., Jurczyszyn, A. J., et al. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12041345 · Cited by 3
“The risk of progression from smoldering multiple myeloma to symptomatic disease is around 50% 5 years from diagnosis [18].”
BackgroundIs It an Ember or Is It a Flame? The Natural History of Smoldering Multiple Myeloma
Kumar, S. K., & Rajkumar, S. V. (2023) · The Hematologist · doi:10.1182/hem.v20.2.202325 · Cited by 3
Self-citationPhysical Activity and Patient-Reported Outcomes in Monoclonal Plasma Cell Disorders
Joseph, J. M., Hillengaß, M., Sweeney, N. W., MOLINA, T. H., Ahlstrom, J. M., Moysich, K. B., Cannioto, R. A., & Hillengaß, J. (2023) · Medicine & Science in Sports & Exercise · doi:10.1249/mss.0000000000003246 · Cited by 3
“MM is preceded by the precursor stages MGUS and SMM, which have an annual risk of progression of about 1% and 10%, respectively (4).”
BackgroundEssential procedures of single-cell RNA sequencing in multiple myeloma and its translational value
Du, J., Gu, X.-R., Yu, X., Cao, Y.-J., & Hou, J. (2023) · Blood Science · doi:10.1097/bs9.0000000000000172 · Cited by 3
An interesting case of systemic lupus erythematosus with multiple myeloma
Basha, F. K. M., Reddy, V. T., Sharma, P., & Vaishnav, B. T. (2023) · Journal of Family Medicine and Primary Care · doi:10.4103/jfmpc.jfmpc_178_22 · Cited by 3
Семочкин, С. В. (2024) · Clinical oncohematology · doi:10.21320/2500-2139-2024-17-2-94-108 · Cited by 3
Cinquanta, L., Tani, M., Sorrentino, M. C., Simula, M. P., Mangraviti, S., Milanesi, B., & Brusca, I. (2016) · La Rivista Italiana della Medicina di Laboratorio - Italian Journal of Laboratory Medicine · doi:10.1007/s13631-016-0130-x · Cited by 3
Therapie des multiplen Myeloms: Was ist gesichert?
Peest, D., Ganser, A., & Einsele, H. (2013) · Der Internist · doi:10.1007/s00108-013-3323-7 · Cited by 3
Renal Disease in Hematological Malignancies
Abdul‐Rahman, I. S. (2011) · Hong Kong Journal of Nephrology · doi:10.1016/s1561-5413(11)60002-1 · Cited by 3
“Patients with smoldering (asymptomatic) MM should not undergo treatment, as current research shows that starting active therapy for people with no symptoms does not improve survival [82].”
Aplicaciones del test sérico de cadenas ligeras libres en las gammapatías monoclonales
López‐Corral, L., García‐Sánz, R., & Miguel, J. F. S. (2010) · Medicina Clínica · doi:10.1016/j.medcli.2010.04.006 · Cited by 4
Fouquet, G., Guidez, S., Herbaux, C., Demarquette, H., & Leleu, X. P. (2013) · La Revue de Médecine Interne · doi:10.1016/j.revmed.2013.08.004 · Cited by 7
Treatment of Smoldering Myeloma: Early or Delayed?
Fermand, J. (2013) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2013.12.008 · Cited by 3
Evolving strategies for the management of multiple myeloma: a managed care perspective.
Im, K., Boccia, R. V., Cannon, E., Cardarelli, W. J., Gamble, B., House, L. S., Dh, H., Malloy, M., Rd, M., Milota, B., et al. (2014) · PubMed · Cited by 3
An Evaluation of Gene Set Analysis for Biomarker Discovery with Applications to Myeloma Research
Qu, P., Tian, E., Barlogie, B., Morgan, G. J., & Crowley, J. J. (2017) · Springer eBooks · doi:10.1007/978-981-10-0126-0_25 · Cited by 3
“Among patients with SMM, about 10% annually will progress to MM within 5 years, and after the 5-year mark the progression rate is similar to MGUS [21].”
BackgroundMonoclonal gammopathies of undetermined significance and smoldering myeloma
Jurczyszyn, A. J., Hutch, R., Waszczuk‐Gajda, A., Suska, A., Krzanowska, K., & Vesole, D. H. (2020) · Acta Haematologica Polonica · doi:10.2478/ahp-2020-0035 · Cited by 4
Ainley, L., Camilleri, M., Chavda, S. J., McMillan, A., Lee, L. S. H., Popat, R., Sillito, F. E., & Yong, K. (2021) · British Journal of Haematology · doi:10.1111/bjh.17969 · Cited by 3
“Smouldering myeloma (SMM) is an asymptomatic stage of multiple myeloma with bone marrow plasma cells >10% or paraprotein >30 g/l, forming a heterogenous group of patients, with variable progression to active myeloma.(1) The SMM standard of care is surveillance to identify early progression.”
BackgroundOjo, A. S., Ojukwu, S. G., Asemota, J., Akinyemi, O. A., Araoye, M. O., Saleh, M., Ali, A. S., & Sarma, R. (2022) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-022-03920-7 · Cited by 3
“The risk in subsequent years remains 1% per year resulting in a cumulative risk of 65% after 10 years of diagnosis, rising to 73% after 15 years (Kyle et al. 2007).”
BackgroundThe promise and harms of screening for plasma cell dyscrasias
Mohyuddin, G. R., Chakraborty, R., & Cliff, E. R. S. (2023) · British Journal of Haematology · doi:10.1111/bjh.18634 · Cited by 3
Will the real myeloma please stand up?
Kumar, S. K., & Rajkumar, S. V. (2013) · Leukemia · doi:10.1038/leu.2012.359 · Cited by 3
Self-citationChevalier, K., Hamroun, S., Bitoun, S., Henry, J., Roux, C., Briot, K., Belkhir, R., Mariette, X., & Séror, R. (2024) · Bone Reports · doi:10.1016/j.bonr.2024.101755 · Cited by 2
“The rate of progression (50 % at 17 months) was much higher than expected in SM (10 % per year during the first 5 years) (Kyle et al., 2007; Kyle et al., 2014).”
BackgroundFunctional Cure as a New Concept of Therapy for Multiple Myeloma
Семочкин, С. В. (2025) · Clinical oncohematology · doi:10.21320/2500-2139-2025-18-2-105-120 · Cited by 3
Alotaibi, G., Saleh, A. S. A., Alhejazi, A., Alahmadi, M. D., Motabi, I., Alsharif, F. Z., Alamer, A., Abduljalil, O., Tailor, I. K., Marei, M. A., et al. (2025) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2025.06.005 · Cited by 3
Screening for Systemic Light-Chain Amyloidosis in Patients Over 60 with λ Monoclonal Gammopathies
Zhou, P., MANSUKHANI, M. M., Yeh, R., Lu, J., Xia, H., Koganti, L., Pang, J., Toskic, D., Scalia, S., Ma, X., et al. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14124146 · Cited by 2
“Progression to AL is not a reliable focus of expectant observation, and AL diagnosis is often too late [4–6].”
Gor, R., Shivakumar, J., Surana, P., Wei, J. X., Murakhovskaya, I., Goldfinger, M., Kornblum, N. S., Shapiro, L. C., Shastri, A., Gupta, R., et al. (2025) · Blood Cancer Journal · doi:10.1038/s41408-025-01337-2 · Cited by 2
Why We Do Not Recommend That People With High‐Risk Smoldering Myeloma Receive Treatment
Mohyuddin, G. R., Lemieux, M., Chakraborty, R., & Gertz, M. A. (2025) · American Journal of Hematology · doi:10.1002/ajh.70159 · Cited by 2
Kan, A. K. C., Chan, B. C. Y., Lau, C. S., & Li, P. H. (2025) · Clinical Reviews in Allergy & Immunology · doi:10.1007/s12016-025-09116-4 · Cited by 3
Prognosis and patterns of progression in smoldering multiple myeloma
Akhlaghi, T., Maclachlan, K. H., Wiggins, A., Usmani, S. Z., Derkach, A., & Hultcrantz, M. L. (2025) · Blood Advances · doi:10.1182/bloodadvances.2025018021 · Cited by 2
Lopes, M. M. D. C., Xavier, L. D. A., Nolasco, S. C. V. M., Ribeiro, S. R., Coutinho, D. F., & Sabino, A. D. P. (2026) · Pharmaceuticals · doi:10.3390/ph19020320 · Cited by 3
“A new concept within the diagnostic criteria revised by the International Myeloma Working Group (IMWG), termed SLiM (S-Sixty), (Li-Light Chains-FLC) and (M-MRI Lesions), emerged and was adopted in 2014 [1,18].”
Rate of MGUS Progression to Haematological Malignancies: A Systematic Review
Quinn, S. J., Cardwell, C. R., Anderson, L. A., & McShane, C. M. (2026) · European Journal Of Haematology · doi:10.1111/ejh.70086 · Cited by 2
“Unlike MGUS, SMM progresses to HM at a rate of 10% per year during the first 5 years after diagnosis, 3% per year for the next 5 years, and 1% per year thereafter [92].”
Redefining light-chain smoldering multiple myeloma: prevalence and progression risk
Maeng, C. V., Þorsteinsdóttir, S., Óskarsson, J. Þ., Rögnvaldsson, S., Long, T. E., Brieghel, C., Andersen, M. N., Ólafsson, A., Þórðardóttir, Á. R., Viðarsson, B., et al. (2026) · Leukemia · doi:10.1038/s41375-026-03028-8 · Cited by 2
“Smoldering multiple myeloma (SMM) is a precursor to multiple myeloma (MM) and present in 0.5% of the population over 40 years old [1, 2].”
InfluentialTwo Cases of Plasma Cell Dyscrasias With Systemic Involvement of Breast
Morris, G. J., Schmidt, P. H., & Jagannath, S. (2014) · Seminars in Oncology · doi:10.1053/j.seminoncol.2014.06.007 · Cited by 2
Dong, L., Chen, C. Y., Ning, B., Xu, D. L., Gao, J., Wang, L. L., Yan, S. Y., & Cheng, S. L. A. (2015) · Genetics and Molecular Research · doi:10.4238/2015.august.14.20 · Cited by 2
“MGUS and SMM are asymptomatic plasma cell dyscrasias, with a propensity to progress to symptomatic MM (Kyle et al., 2007).”
Rajkumar, S. V. (2012) · Elsevier eBooks · doi:10.1016/b978-1-4377-1604-7.00193-7 · Cited by 4
Self-citationIntegrating Emerging Data Into Clinical Practice: A Case-Based Approach for Multiple Myeloma
Sandra Kurtin, P. (2017) · Journal of the Advanced Practitioner in Oncology · doi:10.6004/jadpro.2017.8.4.5 · Cited by 2
“These attributes are associated with a median time to progression (TTP) to active MM of 1.9 years (Kyle et al., 2007).”
InfluentialUllah, A., Omar, N., Savage, N. M., Bollag, R. J., & Singh, G. (2021) · Practical Laboratory Medicine · doi:10.1016/j.plabm.2021.e00240 · Cited by 2
Rare Association between Sarcoidosis and Smoldering Multiple Myeloma: A Case Report
Learned, B. N., Nasiri-Ahad, W., Davis, J. E., Desai, A. G., & Chang, A. (2021) · Cancer Investigation · doi:10.1080/07357907.2021.1988633 · Cited by 2
Is Circulating DNA and Tumor Cells in Myeloma the Way Forward?
Carneiro, E. A., Barahona, F., Pestana, C., & Joao, C. M. (2022) · Hemato · doi:10.3390/hemato3010006 · Cited by 2
“The cut-off for BMPC above 60% in the absence of any symptoms was first introduced by Rajkumar, Larson, and Kyle in 2011 [4] after a reassessment of the 2007 original Mayo Clinic cohort of SMM [82].”
BackgroundGastrointestinal amyloidosis in a patient with smoldering multiple myeloma: A case report
Liu, A., Ding, X., Liu, H., Zhao, W.-J., Jing, X., Zhou, X., Mao, T., Tian, Z., & Wu, J. (2022) · World Journal of Clinical Cases · doi:10.12998/wjcc.v10.i7.2307 · Cited by 2
Identifying monoclonal gammopathy of undetermined significance from electronic health records
Tanenbaum, H. C., Birmann, B. M., Bertrand, K. A., Teras, L. R., Krishnan, A. Y., Pourhassan, H., Goldsmith, S. R., Cannavale, K. L., Wang, S., & Chao, C. (2022) · Cancer Reports · doi:10.1002/cnr2.1755 · Cited by 2
“This observation suggests that the potential misclassification of smoldering MM as MGUS by our ICD-9-based algorithm is small in magnitude given that the progression rate to MM for smoldering MM is expected to be much higher, for example, 10% per year for the first 5 years after diagnosis, whereas that for MGUS is 1%…”
BackgroundPorteous, A., Gibson, S., Eddowes, L. A., Drayson, M. T., Pratt, G., Bowcock, S. J., Willis, F. M., Parkin, H., RENWICK, S. B., Laketic‐Ljubojevic, I., et al. (2023) · Value in Health Regional Issues · doi:10.1016/j.vhri.2023.01.001 · Cited by 2
Understanding high-risk smoldering multiple myeloma
Kreiniz, N., & Gertz, M. A. (2023) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2023.2216818 · Cited by 2
“The 2008 Mayo clinic model [4] defined the following risk factors for SMM progression to MM: the percentage of BMPC of ≥10%, the M-protein of ≥3 g/dl, and an abnormal FLC ratio.”
BackgroundTesta, U., Leone, G. G. M., Pelosi, E., Castelli, G., & Stefano, V. D. (2024) · Mediterranean Journal of Hematology and Infectious Diseases · doi:10.4084/mjhid.2024.044 · Cited by 3
“34 It was estimated that patients with SMM have a higher risk of progression to MM (10%/year) compared to those with MGUS (1%/year).”
BackgroundFerla, V., Farina, F., Perini, T., Marcatti, M., & Ciceri, F. (2024) · Pharmaceuticals · doi:10.3390/ph17070901 · Cited by 2
“Currently, the optimal objective of a score is to identify 50% of patients who progress over two years [26,29,31,32,36–40].”
BackgroundInfluentialSabbah, M., Nguyen, S., Ouzegdouh, M., Choquet, S., Buob, D., Boffa, J. J., Cez, A., & Garderet, L. (2024) · American Journal of Case Reports · doi:10.12659/ajcr.944681 · Cited by 2
“The disease usually starts with asymptomatic monoclonal gammopathy of undetermined significance (MGUS) [1] or smoldering myeloma [2], with initiating genetic abnormalities consisting of hyperdiploidy or immunoglobulin gene translocations [3], and progressively evolves into symptomatic MM with bone…”
BackgroundLi, M., Wu, H., Shou, C., Ye, P., Song, X., Wang, Y., Chen, Y., & Tong, X. (2024) · Discover Oncology · doi:10.1007/s12672-024-01254-z · Cited by 2
“In certain high-risk patients, MGUS and SMM may rapidly advance to symptomatic newly diagnosed multiple myeloma (NDMM) [23].”
BackgroundPatient preferences for intervention in the setting of precursor multiple myeloma
Marinac, C. R., Downey, K., Perry, J. F., Fisher-Longden, B., Rebbeck, T. R., Shah, U. A., O’Donnell, E., Ghobrial, I. M., Nadeem, O., & Egleston, B. L. (2024) · Blood Cancer Journal · doi:10.1038/s41408-024-01161-0 · Cited by 2
Smoldering multiple myeloma: Integrating biology and risk into management
Patel, R., Hill, E., & Dhodapkar, M. V. (2024) · Seminars in Hematology · doi:10.1053/j.seminhematol.2024.10.002 · Cited by 2
Mitani, K., Horino, T., Terada, Y., Okuhara, Y., & Hatakeyama, Y. (2024) · Clinical and Experimental Nephrology · doi:10.1007/s10157-024-02571-x · Cited by 2
“MGRS renal disease is diagnosed by demonstrating monoclonal deposits in the kidney, making pathological evaluation through renal biopsy mandatory [3].”
Liu, Y., Desai, P. M., Nadeem, O., Woyach, J. A., & Alsouqi, A. (2025) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk-25-473650 · Cited by 3
Yu, W., Zhan, J., Wang, Y., Cao, X., Yü, A., Rao, Y., Huang, C., Zhang, X., Lu, S., Liu, Y., et al. (2025) · Journal of Translational Medicine · doi:10.1186/s12967-025-07098-7 · Cited by 2
“Although MGUS and SMM are largely asymptomatic, longitudinal studies estimate annual progression rates of approximately 1% and 10%, respectively [27, 28].”
Yi, J. H., Yoon, D. H., & Kım, K. (2025) · Seminars in Hematology · doi:10.1053/j.seminhematol.2025.11.003 · Cited by 2
Manifestaciones osteoarticulares por amiloidosis sistémica
Toro, C. E., Duque, M. A. Q., Restrepo, J. F., Rondón, F., Páez, O., & Gamarra, A. I. (2007) · Revista Colombiana de Reumatología · Cited by 2
Annual clinical updates in hematological malignancies: a continuing medical education series
(2017) · American Journal of Hematology · doi:10.1002/ajh.24907 · Cited by 3
Amyloidosis with Multiple Myeloma Presenting with Acromegalic Features.
Bhatty, S. A., Siddiqui, A. S., Talib, A., Mahmood, K., Naqvi, I., Khan, A. N., Nizam, M., & Saiyed, A. (2015) · PubMed · doi:10.2015/jcpsp.s112s114 · Cited by 2
Progression risk for MGUS and SMM
Greipp, P. R. (2007) · Blood · doi:10.1182/blood-2007-07-097667 · Cited by 2
S0120 G.E.M.S.: genomics encounters MGUS and SMM
Dispenzieri, A. A. (2014) · Blood · doi:10.1182/blood-2013-11-535575 · Cited by 2
Self-citationAmiloidosis de cadera. Presentación de un caso y revisión de la bibliografía
Cambero, R. P., Rivera, I., & Arévalo, A. S. (2011) · Revista Española de Cirugía Ortopédica y Traumatología · doi:10.1016/j.recot.2011.03.010 · Cited by 2
Withofs, N., Nanni, C., Simoni, P., Fanti, S., Beguin, Y. P., & Caers, J. (2015) · Clinical and Translational Imaging · doi:10.1007/s40336-015-0119-x · Cited by 2
Is it time for preemptive drug treatment of asymptomatic (smoldering) multiple myeloma?
Fawole, A. A., Abonour, R., Stender, M., Shatavi, S. V., Gaikazian, S. S., Anderson, J., & Jaiyesimi, I. A. (2014) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428194.2014.897702 · Cited by 2
“Reference Study design Intervention Patients Outcome/comment Hjorth and Hellquist, 1993 [35] Randomized control trial Immediate vs. deferred MP 50 MGUS/AMM (25/25) Similar response rate, response duration and survival but increased risk of 2nd malignancy in early therapy group Rajkumar et al ., 2001 [40] Single-arm pi…”
BackgroundInfluentialChang, C., Su, M.-J., Lee, S.-J., Tsai, Y.-H., Kuo, L.-Y., Lin, I.-H., Huang, H., Yen, T., & Chu, F. (2016) · Asian Pacific Journal of Cancer Prevention · doi:10.7314/apjcp.2016.17.1.395 · Cited by 2
“Monoclonal gammopathy of undetermined significance (MGUS), instead, is clinically asymptomatic with few infiltrates of plasma cell in the bone marrow and the presence of monoclonal protein in serum (Kyle et al., 2010).”
BackgroundMonoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma
Kastritis, E., & Dimopoulos, M. A. (2013) · Cambridge University Press eBooks · doi:10.1017/cbo9780511862465.010 · Cited by 2
Lymphoma and Myeloma of the Sacrum
Mavrogenis, A. F., Panagopoulos, G. N., Angelini, A., Zinzani, P. L., & Ruggieri, P. (2017) · Springer eBooks · doi:10.1007/978-3-319-51202-0_18 · Cited by 2
Salem, D., Korde, N., Venzon, D. J., Liewehr, D. J., Marić, I., Calvo, K. R., Braylan, R. C., Tembhare, P. R., Yuan, C. M., Landgren, O., et al. (2017) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2017.1321746 · Cited by 2
Multiples Myelom: Was ist gesichert in der Therapie?
Baertsch, M., & Goldschmidt, H. (2017) · Der Internist · doi:10.1007/s00108-017-0337-6 · Cited by 2
Lakshman, A., Ravi, P. K., Rajkumar, S. V., & Kumar, S. K. (2018) · Leukemia · doi:10.1038/s41375-018-0155-4 · Cited by 2
“8 years in the Mayo Clinic cohort used to develop the popular risk stratification system [8].”
MethodSelf-citationA Mathematical Model for Tumor–Immune Dynamics in Multiple Myeloma
Gallaher, J. A., Larripa, K., Ledzewicz, U., Renardy, M., Shtylla, B., Tania, N., White, D., Wood, K., Zhu, L., Passey, C., et al. (2018) · Association for Women in Mathematics series · doi:10.1007/978-3-319-98083-6_5 · Cited by 4
“SMM patients have a 10% annual risk of progressing to MM for the first five years following diagnosis [49].”
BackgroundMinimal residual disease in multiple myeloma 2019
Kunacheewa, C., Lin, P., & Manasanch, E. E. (2019) · Advances in Cell and Gene Therapy · doi:10.1002/acg2.71 · Cited by 2
Skelettveränderungen bei Plasmazelldyskrasien
Weber, T. F., & Mokry, T. (2021) · Der Radiologe · doi:10.1007/s00117-021-00932-1 · Cited by 2
Multiple Myeloma and the Kidney
Rana, R., Cockwell, P., & Pinney, J. H. (2022) · Springer eBooks · doi:10.1007/978-3-030-76419-7_49 · Cited by 2
Updates in Plasma Cell Dyscrasias and Related Monoclonal Immunoglobulin-Mediated Renal Disease
Midha, S., Nadeem, O., & Selamet, U. (2022) · Seminars in Nephrology · doi:10.1016/j.semnephrol.2023.151352 · Cited by 3
Radiation Therapy in Multiple Myeloma
Greenberger, J. S. (2010) · Humana Press eBooks · doi:10.1007/978-1-60761-554-5_4 · Cited by 2
Molecular Genetics of Multiple Myeloma
Bi, C., & Chng, W.-J. (2010) · Wiley eBooks · doi:10.1002/9780470015902.a0022446 · Cited by 2
Levinson, S. S. (2009) · Wiley eBooks · doi:10.1002/9780470015902.a0001136.pub2 · Cited by 2
Controversies in smoldering multiple myeloma: finding the optimal approach for treatment initiation
Ludwig, H., & Schreder, M. (2024) · The Oncologist · doi:10.1093/oncolo/oyae266 · Cited by 2
Smouldering Myeloma: Chasing a Hyperviscous Sample
Birdi, A., Sinha, A., Banerjee, M., & SelviN, M. K. (2021) · Indian Journal of Clinical Biochemistry · doi:10.1007/s12291-021-00990-1 · Cited by 1
Abdallah, N. H., Witzig, T. E., Kumar, S. K., Lacy, M. Q., Hayman, S. R., Dispenzieri, A. A., Roy, V., Gertz, M. A., Bergsagel, P. L., & Rajkumar, S. V. (2024) · Leukemia · doi:10.1038/s41375-024-02192-z · Cited by 1
“It is associated with a yearly risk of progression to MM of approximately 10% in the fi rst 5 years, 3% in the following 5 years, and 1% thereafter [2].”
Self-citationPelli, A. C., Schiffbauer, V., Tommasa, S. D., Ulrich, R., Reinert, A., Gerlach, K., & Völker, I. (2024) · Equine Veterinary Education · doi:10.1111/eve.14035 · Cited by 1
Evaluation of Plasma Cell Neoplasms
Roshal, M., Gao, Q., Hutcherson, S. M., Thoren, K. L., Zhu, M., & Murata, K. (2024) · Wiley eBooks · doi:10.1002/9781683674023.ch109 · Cited by 2
Risk stratification and early intervention in smoldering multiple myeloma
Sra, M. S., & Kumar, S. K. (2025) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2025.2576562 · Cited by 1
“…the first five years following diagnosis, decreasing to 3% annually during years six to ten, and 1% per year thereafter, paralleling that of MGUS [10]. to account for this variability, multiple risk stratification models have been developed to identify individuals at the highest risk of…”
InfluentialKikuchi, T. (2025) · International Journal of Hematology · doi:10.1007/s12185-025-04096-9 · Cited by 1
“SMM occurs in approximately 0.5% of individuals aged ≥ 40 years, with an estimated progression rate of approximately 10% per year during the first 5 years after diagnosis and 1.5% per year thereafter [8, 9].”
InfluentialTo treat or not to treat: a state-of-the-art overview of smoldering multiple myeloma
Garg, A., & Devarakonda, S. S. (2026) · Frontiers in Hematology · doi:10.3389/frhem.2025.1706219 · Cited by 1
Yi, J. H., Yoon, D. H., Park, S., Min, C., Lee, J. H., Jung, S., Koh, Y., Lee, H. J., Jo, J., & Kim, K. (2026) · Annals of Hematology · doi:10.1007/s00277-026-06851-2 · Cited by 1
“%) remaining progression-free to MM[14].”
InfluentialEl‐Sehrawy, A. A. M. A., Oriquat, G., Saidov, S., Ruzikulov, U., Shakhmurova, G., Jbl, B. J., Singhal, D., & Shefali (2026) · Clinica Chimica Acta · doi:10.1016/j.cca.2026.121066 · Cited by 1
Haslam, A., Iqbal, G., Drayson, M. T., Pratt, G., Yong, K., Dunn, J., Atkin, C., Bunce, C., Howe, D., & Bowcock, S. J. (2026) · British Journal of Haematology · doi:10.1111/bjh.70492 · Cited by 1
“8,9 Within modern cohorts followed up according to IMWG imaging guidelines (advanced base-line imaging for all, with yearly WB-MRI for SMM), a much lower prevalence of fractures is observed.”
Chen, H., Ren, H., Wang, X. W., Liu, C., Jiang, L., Zang, S., Liu, T., Wang, S., Huang, W., & Zhou, L. (2026) · Molecular and Cellular Probes · doi:10.1016/j.mcp.2026.102073 · Cited by 1
Metadata
- Authors
- Kyle, R. A., Remstein, E. D., Therneau, T. M., Dispenzieri, A., Kurtin, P. J., Hodnefield, J. M., Larson, D. R., Plevak, M. F., Jelinek, D. F., Fonseca, R., Melton, L. J., & Rajkumar, S. V.
- Affiliations
- Mayo Clinic (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2007-06-21
- Volume
- 356
- Issue
- 25
- Pages
- 2582-2590
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W1974983065
- Cited by
- 921
- References
- 25
- Citations by year
- 2026: 34 · 2025: 57 · 2024: 62 · 2023: 48 · 2022: 56 · 2021: 69 · 2020: 70 · 2019: 45 · 2018: 49 · 2017: 37 · 2016: 55 · 2015: 46 · 2014: 50 · 2013: 56 · 2012: 42
- FWCI
- 21.52
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Cancer Institute (CA 107 476, CA6 2242, R01CA107476, P01CA062242)
- Topics
- Health Sciences › Medicine › Hematology › Multiple Myeloma Research and Treatments
- Health Sciences › Medicine › Internal Medicine › Amyloidosis: Diagnosis, Treatment, Outcomes
- Health Sciences › Medicine › Hematology › Chronic Lymphocytic Leukemia Research
- Keywords
- smoldering multiple myeloma, asymptomatic multiple myeloma, amyloidosis, prognostic factors, risk stratification, clinical course
- MeSH terms
- Adult, Aged, Aged, 80 and over, Amyloidosis, Antibodies, Monoclonal, Biopsy, Bone Marrow Cells, Bone Marrow Examination, Female, Humans, Male, Middle Aged, Multiple Myeloma, Plasma Cells, Prognosis, Risk Factors, Cohort Studies, Disease Progression, Lymphocyte Count
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.